Related Experiment Video
Updated: Aug 4, 2026
11:13
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
8.8K
Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth
Zhiqiang Ku1, Xuping Xie2, Jianqing Lin3
1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Biorxiv : the Preprint Server for Biology
|February 8, 2022
Summary
Engineered bispecific antibodies (bsAbs) offer a cost-effective COVID-19 therapy alternative. One bsAb design (14-H-06) shows enhanced neutralization against SARS-CoV-2 variants, outperforming antibody cocktails.
Area of Science:
- Immunology
- Virology
- Biotechnology
Background:
- Neutralizing antibody therapy for COVID-19 faces limitations due to antibody resistance, necessitating expensive antibody cocktails.
- Bispecific antibodies (bsAbs) are engineered to target multiple epitopes simultaneously, potentially overcoming resistance and simplifying treatment.
Conclusions:
- Rationally engineered bsAbs, particularly the IgG-(scFv)2 design, represent a promising and cost-effective strategy to improve COVID-19 therapy.
- Optimized bsAbs can enhance potency and broaden the neutralizing spectrum against SARS-CoV-2 variants, offering an alternative to complex antibody cocktails.
